세계의 카페시타빈 시장 : 증상별, 합성 유형별, 예측(2023-2032년)

Capecitabine market size is projected to expand at 4.9% CAGR from 2023 to 2032. The rising incidence of various cancers, including breast and colorectal is fueling the demand for several effective chemotherapy drugs.

The rapid advancements in cancer treatment protocols is driving the adoption of capecitabine as an oral chemotherapy option. Additionally, the ongoing R&D activities along with the rising number of product approvals are leading to improved efficacy and safety of capecitabine. For instance, in December 2022, the U.S. FDA approved the updated labeling for capecitabine tablets as part of Project Renewal. This initiative, led by the Oncology Center of Excellence, aims to ensure clinically meaningful as well as scientifically up-to-date information for specific older oncology drugs.

The growing aging population across the globe coupled with the increasing cancer awareness is underscoring the significance of capecitabine in addressing the growing burden of cancer. The convenience of oral administration and reduced hospital visits for enhanced patient compliance are other factors driving the market growth.

The capecitabine industry is segregated into indication, synthesis type, mode, and region.

Based on indication, the industry value from the colorectal cancer segment is estimated to rise at 5.3% CAGR through 2032. The increasing prevalence of colorectal cancer and the surging advancements in cancer treatment protocols is driving the efficacy of capecitabine as a chemotherapy option. The effectiveness of capecitabine in treating colorectal cancer will, thus, add to the segment growth.

Capecitabine market share from the biological API synthesis type segment is projected to increase at 4.9% CAGR from 2023 to 2032. This growth is ascribed to the growing advancements in biotechnology, the increasing demand for targeted therapies, and the efficacy of biologically synthesized active pharmaceutical ingredients. The development of capecitabine through biological synthesis will further contribute to its relevance and adoption in the pharmaceutical sector.

Regionally, the Asia Pacific capecitabine industry is slated to expand at 5.7% CAGR from 2023 to 2032, driven by the increasing incidence of breast and colorectal cancers. The rising advancements in healthcare infrastructure, increasing awareness of cancer treatment options, and the growing aging population will further drive the consumption of capecitabine across the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast calculation
• 1.4 Covid-19 impact analysis at global level
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Capecitabine market 360 degree synopsis, 2018 - 2032 (USD Million)
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Indication trends
  • 2.1.4 Synthesis type trends
  • 2.1.5 Mode trends

Chapter 3 Capecitabine Market Insights

• 3.1 Industry ecosystem analysis
• 3.2 COVID-19 impact analysis
• 3.3 Regulatory landscape
  • 3.3.1 U.S.
  • 3.3.2 Europe
• 3.4 Pricing analysis, by region (USD Million)
  • 3.4.1 Selling price in USD per kg
• 3.5 Innovation & sustainability
• 3.6 Industry impact forces
  • 3.6.1 Growth drivers
    • 3.6.1.1 Increasing incidences of cancer
    • 3.6.1.2 Surging demand for generics
    • 3.6.1.3 Rising drug related research and development activities
  • 3.6.2 Industry pitfalls & challenges
    • 3.6.2.1 High manufacturing cost
• 3.7 Growth potential analysis
  • 3.7.1 By indication
  • 3.7.2 By synthesis type
  • 3.7.3 By mode
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Strategic outlook matrix, 2022
• 4.3 Company market share analysis
  • 4.3.1 Global
  • 4.3.2 North America
  • 4.3.3 Europe
  • 4.3.4 Asia Pacific
• 4.4 Production capacity
• 4.5 List of top 20 end consumers with contact details/email id
• 4.6 Competitive positioning matrix, 2022

Chapter 5 Capecitabine Market Estimates and Forecast, By Indication, 2018 - 2032 (USD Million)

• 5.1 Key trends, by indication
• 5.2 Breast cancer
• 5.3 Colorectal cancer
• 5.4 Gastric cancer
• 5.5 Pancreatic cancer
• 5.6 Other indications

Chapter 6 Capecitabine Market Estimates and Forecast, By Synthesis Type, 2018 - 2032 (USD Million)

• 6.1 Key trends, by synthesis type
• 6.2 Chemical based API
• 6.3 Biological API
• 6.4 Highly potent API (HPAPI)

Chapter 7 Capecitabine Market Estimates and Forecast, By Mode, 2018 - 2032 (USD Million)

• 7.1 Key trends, by mode
• 7.2 In-house manufacturing
• 7.3 Contract manufacturing

Chapter 8 Capecitabine Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

• 8.1 Key trends, by region
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Russia
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Malaysia
  • 8.4.7 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East & Africa

Chapter 9 Company Profiles

• 9.1 Sun Pharmaceutical Industries Ltd
• 9.2 Shilpa Medicare limited
• 9.3 Atom Pharma
• 9.4 Global Calcium
• 9.5 LGM Pharma
• 9.6 Dr. Reddy's Laboratories Ltd
• 9.7 Cipla Ltd
• 9.8 Zeon Pharma
• 9.9 Avanscure Lifesciences Pvt Ltd
• 9.10 Hepartex